India to Malaysia: Salbutamol Export Trade Route

The India to Malaysia Salbutamol corridor is one of India's established pharmaceutical export routes, with 353 shipments documented worth a combined $4.9M USD. The route is dominated by MEDISPRAY LABORATORIES PRIVATE LIMITED, which alone accounts for roughly 52% of all export value, reflecting the consolidated nature of India's salbutamol manufacturing sector.

Across 26 active suppliers, the average shipment value stands at $14.0K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 71% of all shipments, consistent with salbutamol's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 30 days port-to-port. The route has recorded an annual growth rate of 34.3%, placing it at rank #5 among India's top salbutamol export destinations globally.

On the import side, key buyers of Indian salbutamol in Malaysia include CIPLA MALAYSIA SDN BHD, CIPLA MALAYSIA SDN BHD , CIPLA MALAYSIA SDN BHD, and 23 others. CIPLA MALAYSIA SDN BHD is the single largest importer with 115 shipments valued at $2.7M USD.

India's salbutamol exports to Malaysia are driven primarily by a handful of large-scale manufacturers. MEDISPRAY LABORATORIES PRIVATE LIMITED with 110 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 26 active exporters signals a competitive but concentrated market — buyers in Malaysia benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — MEDISPRAY LABORATORIES PRIVATE LIMITED, MEDISPRAY LABORATORIES PRIVATE LIMITED , CIPLA LIMITED — together account for 88% of total trade value on this route. The average shipment value of $14.0K USD reflects a mix of bulk commercial orders and smaller specialty shipments.

Beyond the primary product category, shipments on this route include closely related formulations such as asthalin 100mcg inhaler (salbutamol sulphate ) (1 x 200 md) and asthalin 100 mcg inhaler (salbutamol sulphate ) ., suggesting that buyers in Malaysia tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, CIPLA MALAYSIA SDN BHD is the largest importer with 115 shipments worth $2.7M USD — representing 54% of all salbutamol imports from India on this route. A total of 26 buyers are active on this corridor.